Clinical trial
Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal…
NCT00165217 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00165217 |
|---|---|
| Title | Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma |
| Official title | A Phase II Trial of Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Capecitabine, Thalidomide |
| Enrollment | 37 |
| Start date | Nov 1, 2001 |
| Primary completion | Dec 1, 2005 |
| Completion | Dec 1, 2005 |
| First posted | Sep 14, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: